Introduction
TAK-164
TAK-164 is a novel second-generation anti-guanylyl cyclase C (GCC) antibody–drug conjugate (ADC), consisting of a human immunoglobulin (IgG)1 monoclonal antibody (mAb) specifically targeting GCC, linked to a novel class of DNA alkylating agents termed mono-indolinobenzodiazepine pseudodimers (IGNs), by a peptide linker [TAK-264, a first-generation anti-GCC ADC consisting of a mAb linked to a microtubule inhibitor, monomethyl auristatin, demonstrated preclinical highly specific cytotoxic activity [